Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSun Young Rha, Xiaochun Zhang, Juan Manuel O’Connor et al.|The Lancet Oncology|2023Cited by 614
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion studyNehal J. Lakhani, Wells A. Messersmith, Laura Q.M. Chow et al.|Seoul National University Open Repository (Seoul National University)|2021Cited by 95
ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).Se Hoon Park, Won Ki Kang, Dae Young Zang et al.|Journal of Clinical Oncology|2019Cited by 79
Gastrointestinal malignancies harbor actionable MET exon 14 deletionsJeeyun Lee, Kyoung‐Mee Kim|Oncotarget|2015Cited by 61
<i>NTRK1</i> rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell lineSu Jin Lee, Jeeyun Lee|Oncotarget|2015Cited by 58